Clinical Trials Browser

Interventional × Synovitis, Pigmented Villonodular × Clear all

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Phase 2 Completed

17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05417789 2026-02-02

TANGENT

Phase 3 Active not recruiting

128 enrolled

Synovitis, Synovitis, Pigmented Villonodular

NCT03069469 2025-12-18

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Phase 1/2 Active not recruiting

120 enrolled

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05804045 2025-09-08

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Phase 3 Active not recruiting

90 enrolled

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05059262 2025-02-24

MOTION

Phase 3 Active not recruiting

123 enrolled 19 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT05349643 2024-07-05

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

Phase 2 Completed

20 enrolled

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT04731675 2024-06-27

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Phase 2 Completed

11 enrolled 21 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02371369 2022-05-11

ENLIVEN

Phase 3 Completed

120 enrolled 25 charts 1 FDA

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02471716 2021-08-31

FPA008-002

Phase 1/2 Completed

66 enrolled 20 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT03291288 2021-05-14

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

Phase 1 Completed

32 enrolled 22 charts

Synovitis, Pigmented Villonodular

NCT01643850 2021-01-05

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Phase 2 Completed

36 enrolled 38 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

NCT02673736 2018-08-02

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Phase 1 Terminated

11 enrolled

Giant Cell Tumor of Tendon Sheath, Joint Diseases, Neoplasms, Synovitis, Synovitis, Pigmented Villonodular

NCT01261429 2013-04-16

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Phase 2 Completed

50 enrolled

Synovitis, Pigmented Villonodular

Clinical Trials

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

TANGENT

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

MOTION

A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

ENLIVEN

FPA008-002

Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)